mRNA-1273 SARS-CoV-2疫苗随机对照2期试验安全性与免疫原性初步报告
该2期随机观察者盲法安慰剂对照试验在美国8个中心纳入600名18岁以上健康成人,按年龄分层后1:1:1随机接受50μg或100μg mRNA-1273或安慰剂,间隔28天肌肉注射两剂。结果显示常见 solicited 不良反应为注射部位疼痛、头痛和疲劳,100μg剂量首剂后结合抗体和中和抗体高于50μg,第二剂后14天抗体水平超过恢复期血清并持续至第57天,安全性可接受。
要点
- mRNA-1273两剂方案在18岁以上成人中诱导显著免疫应答,安全性可接受。
- 首剂后28天100μg剂量结合抗体和中和抗体高于50μg,第二剂后差异减小。
- 第二剂后14天抗体水平超过恢复期血清,并持续升高至第57天。
核心结论
- mRNA-1273 50μg和100μg两剂方案在18岁以上成人中安全性和免疫原性可接受,诱导显著SARS-CoV-2免疫应答。
研究设计与样本
- 2期随机观察者盲法安慰剂对照试验,在美国8个中心开展,纳入600名18岁以上无SARS-CoV-2感染史或风险的健康成人。
- 参与者按年龄分层(≥18-<55岁和≥55岁),1:1:1随机接受50μg或100μg mRNA-1273或安慰剂,间隔28天肌肉注射两剂。
主要发现
- 两年龄组每次接种后最常见 solicited 不良反应为注射部位疼痛、头痛和疲劳。
- 首剂后28天,100μg剂量诱导的结合抗体和中和抗体高于50μg剂量,第二剂后该差异不明显。
- 第二剂后14天(第43天)结合抗体和中和抗体大幅升高,超过恢复期血清水平,并持续至第57天。
- 一例严重不良事件发生在首剂后33天,研究者判定与疫苗无关。
临床怎么用
- 为mRNA-1273后续效力和3期试验提供50μg和100μg两剂方案的安全性与免疫原性依据。
局限性
- 本文为初步报告,样本量600例,随访至第57天,长期安全性和免疫持久性未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vaccines are urgently needed to prevent the global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We assessed the safety and immunogenicity of vaccine candidate mRNA-1273, encoding the prefusion-stabilized spike protein of SARS-CoV-2. METHODS: This phase 2, randomized, observer-blind, placebo-controlled trial was conducted at 8 sites in the USA, in healthy adults aged ≥18 years with no known history or risk of SARS-CoV-2 infection, and had not previously received an investigational CoV vaccine or treatment. Participants were stratified into two age cohorts (≥18-<55 and ≥55) and were randomly assigned (1:1:1) to either 50 or 100 µg of mRNA-1273, or placebo administered as two intramuscular injections 28 days apart. The primary outcomes were safety, reactogenicity, and immunogenicity assessed by anti-SARS-CoV-2-spike binding antibody level (bAb). Secondary outcome was immunogenicity assessed by SARS-CoV-2 neutralizing antibody (nAb) response. RESULTS: Between 29 May and 8 July 2020, 600 participants were randomized, 300 per age cohort. The most common solicited adverse reactions were pain at injection site, headache, and fatigue following each vaccination in both age cohorts. One serious adverse event deemed unrelated by the site investigator occurred 33 days post-vaccination one. mRNA-1273 induced bAb and nAb by 28 days post-vaccination one that were higher at the 100 µg dose relative to the 50 µg dose; this difference was less apparent post-vaccination two. Binding antibodies and nAb increased substantially by 14 days following the second vaccination (day 43) to levels exceeding those of convalescent sera and remained elevated through day 57. CONCLUSIONS: Vaccination with mRNA-1273 resulted in significant immune responses to SARS-CoV-2 in participants 18 years and older, with an acceptable safety profile, confirming the safety and immunogenicity of 50 and 100 µg mRNA-1273 given as a 2 dose-regimen. ClinicalTrials.gov; NCT04405076.
引用
- Chu L, McPhee R, Huang W, et al. A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine. 2021. PMID: 33707061. doi:10.1016/j.vaccine.2021.02.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。